Alzamend Neuro (ALZN) Q4 2024 earnings summary

Executive summary

• Focused on developing AL001 (ionic lithium cocrystal) and ALZN002 (cell-based immunotherapy) for Alzheimer's, BD, MDD, and PTSD, both in early clinical stages.

• No revenue generated; operations funded by equity and preferred stock issuances, with ongoing net losses and negative cash flows.

• Substantial doubt exists about ability to continue as a going concern; additional capital is required for continued operations and clinical trials.

Financial highlights

• Net loss for FY 2024 was $9.95 million, a 33% improvement from $14.88 million in FY 2023.

• Research and development expenses decreased 13% to $6.46 million; general and administrative expenses fell 53% to $3.48 million.

• Cash at April 30, 2024 was $376,000, down from $5.1 million a year earlier.

• No revenue recognized in FY 2024 or FY 2023.

Outlook and guidance

• Plans to initiate Phase II clinical trials for AL001 in Alzheimer's, BD, MDD, and PTSD in 2025, pending additional funding.

• ALZN002 Phase I/IIA trial paused in February 2024 due to CRO termination; expected to resume in 2H 2024.

• Management believes recent preferred stock financings may support operations for the next twelve months, but further capital will be needed for full clinical development.